February 18th 2025
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.
Americans Show New Interest in Virtual Eye Care Options
February 11th 2021Young adults, in particular, are more likely to seek out and place high value on telemedicine for eye care and those in vulnerable populations are benefitting most, according to an annual vision wellness study by VersantHealth.
Read More
Impact of Vision Care, Specifically Diabetic Retinopathy, on Older Adults
October 30th 2020Falls are the current leading cause of injuries for older Americans, and many of them result in permanent disability and fatalities. The risk of falling for older adults doubles if they have impaired vision from a degenerative eye disease like diabetic retinopathy.
Read More
Time to Revise Hydroxychloroquine, Retinopathy Guidelines, Say Authors
October 21st 2020Rather than stopping hydroxychloroquine altogether, doses could be reduced and patients monitored if there are signs of retinopathy, say the authors of a commentary in the American Journal of Ophthalmology.
Read More
Headaches Behind the Eyes – Triggers, Treatments and How to Prevent Them
October 21st 2020Across the world, almost everyone has experienced a bad headache and knows the unpleasant symptoms that can come with it. Many have also faced migraines, which can cause dizziness, nausea and stomach pain - as well as impacting your vision.
Read More